White Paper: Implications of COVID-19 Pandemic on ESG Investing and Health Care/Biotech Sector


Categories: ,


As of mid-July, more than 14.3 million people worldwide have been infected with SARS-CoV, the virus that causes COVID-19. Of those, more than 602,750 have died. In the US, cases have reached over 3.7 million with over 142,000 deaths.

The COVID-19 pandemic continues to be a major factor in the financial markets as it impacts the economy, strains health care systems and government budgets.

Stocks will see more turmoil in the second half of 2020 as vaccine developments – positive and negative – continue to impact the markets on a daily basis.

The white paper examines the opportunities and challenges created by the COVID-19 pandemic on two sectors – Environmental, Social and Governance (ESG) and health care/biotech.

White paper provides snapshot view of what specific companies are doing in molecular diagnostic testing, antibody testing, therapeutics and vaccines. Tables include company stocks, return YTD, 52-week highs.

55 pages including tables, graphs and footnotes.

Table of Contents


Environmental, Social and Governance                         

S and G increase in importance

Innovations creating specific investment opportunities


More managers launch ESG funds

Health Care/Biotech                                                            

Molecular Diagnostic Tests

Antibody Tests



Stock prices in the health care sector


Listing of stocks in the CNBC COVID-19 Index Tracker

BIO’s listing of vaccine stocks


 About Peltz International